![Garry Michael Kann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Garry Michael Kann
Corporate Officer/Principal chez
ENDONOVO THERAPEUTICS, INC.
Profil
Garry Michael Kann is currently the Head of Corporate Development at Endonovo Therapeutics, Inc. and a Partner at The Firebird Partnership Ltd. He obtained an undergraduate degree from Kean University.
Postes actifs de Garry Michael Kann
| Sociétés | Poste | Début |
|---|---|---|
| ENDONOVO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2022 |
The Firebird Partnership Ltd.
 The Firebird Partnership Ltd. Financial ConglomeratesFinance Provides investment services | Corporate Officer/Principal | - |
Formation de Garry Michael Kann
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
8
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Endonovo Therapeutics, Inc.
 Endonovo Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops off the shelf regenerative products that no longer require the injection of stem cells | Health Technology |
Kean University
 Kean University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Firebird Partnership Ltd.
The Firebird Partnership Ltd. Financial ConglomeratesFinance Provides investment services | Finance |
